Drug Discovery World

JANUARY 18, 2023

The US Food and Drug Administration (FDA) and CN Bio have expanded their collaboration for the second time, with new research aiming to evaluate multi-organ microphysiological systems (MPS) using the PhysioMimix Multi-organ System. . Bioavailability is defined as the fraction of drug reaching the bloodstream.

Bioavailability 52

Bioavailability In-Vitro Research Drugs 52

Drug Discovery World

JANUARY 24, 2024

DDW’s Megan Thomas caught up with Wigerinck to learn more about his work with small molecules for fibrosis research. MT: Your appointment comes as Fibrocor seeks to advance two drug candidates – exquisitely specific kinase inhibitor small molecules (FIB992 and FIB991) for rare indications into the clinic.

Research 57

Research Gene Expression Drugs Development 57

pharmaphorum

NOVEMBER 9, 2022

Meanwhile, NRG’s in vitro studies have shown its INDs to protect mitochondria and increase the viability of human cells, potentially able to halt or significantly slow progression of diseases such as Parkinson’s and ALS. Currently, the treatments available only provide management of symptoms of chronic neurodegenerative disorders.

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

Drug Discovery World

AUGUST 3, 2022

Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. Ensuring that the CPP can escape this endosomal compartment is crucial for its bioavailability and bioactivity properties. Nanoparticles 6.

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

The Pharma Data

DECEMBER 9, 2020

Spun out of CEO and co-founder Evan Feinberg’s breakthrough artificial Intelligence (AI) research at Stanford University’s Pande Lab , Genesis Therapeutics is applying the resulting influential PotentialNet neural network algorithm to unify AI and biotech against a range of diseases with unmet needs. which will remain a key shareholder.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

The Pharma Data

OCTOBER 21, 2020

Research s howed KB-0742 i nhibited a ndrogen r eceptor -d ependent a ctivity and r educed t umor g rowth in c astration -r esistant p rostate c ancer. We designed KB-0742 to be an orally bioavailable CDK9 inhibitor with a differentiated selectivity profile,” said Norbert Bischofberger, Ph.D., SAN MATEO, Calif., and CAMBRIDGE, Mass.,

In-Vivo 40

In-Vivo In-Vitro Bioavailability Clinical Trials 40

Pharmaceutical Technology

MAY 31, 2023

CFT8919 is an orally bioavailable BiDAC degrader designed to exhibit potent and selective activity against EGFR L858R in patients with non-small cell lung cancer (NSCLC). The agreement will cover the Hong Kong special administrative region (SAR), the Macau SAR and Taiwan.

Bioavailability 130

Bioavailability In-Vivo In-Vitro Licensing 130